Skip to main content

Advertisement

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole

Fig. 1

The 1-year incidence rates of pneumocystis pneumonia in treatment episodes with various ranges of steroid doses. Notably, the incidence was considerably higher for daily doses of steroids ≥ 15 mg of prednisone or equivalent. Error bar indicates the upper margin of the 95% confidence interval of the incidence rate

Back to article page